Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02872701 · ClinicalTrials.gov registry record · Phase 2

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

A Phase 2 study, sponsored by On Target Laboratories.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target

NCT02872701: Completed Phase 2 study, sponsored by On Target Laboratories.

NCT02872701 is a Phase 2 study that has completed, run by On Target Laboratories. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02872701, a Phase 2 study, has completed, sponsored by On Target Laboratories.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target

Study Summary

This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.

Primary Outcome

Sensitivity or True Positive Rate (TPR) for OTL38 in combination with fluorescent light, defined as the proportion of fluorescent light positive tissue samples (nodule, synchronous lesion, and margin but excluding lymph nodes) that are histologically confirmed to be FR+ and lung cancer by central pathology relative to the total number of tissue samples confirmed to be FR+ and lung cancer by central pathology. Sensitivity = (True Positive)/(True Positive +False Negative)

Interventions

  • DRUG OTL38 for Injection
  • DEVICE Near infrared camera imaging system
  • PROCEDURE Endoscopic or Thoracic Surgery

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2017-05-04
Est. Completion 2018-11-30
Phase Phase 2
On Target Laboratories

4 total trials

What the finished NCT02872701 record still lists

NCT02872701 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).

The record links to 0 conditions, and to 3 interventions - of which OTL38 for Injection is the first listed.

NCT02872701 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02872701 about?

NCT02872701 is a clinical study titled "OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules". This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared I...

What is the current status of trial NCT02872701?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2017-05-04. Estimated completion is 2018-11-30.

What interventions are being tested in trial NCT02872701?

The interventions under investigation include: OTL38 for Injection (DRUG), Near infrared camera imaging system (DEVICE), Endoscopic or Thoracic Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT02872701?

This trial is sponsored by On Target Laboratories, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02872701's enrollment target sits among peer trials

100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02872701, the US trial registry maintained by the National Library of Medicine. NCT02872701 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.